Friday 6 November 2026 Export RVMD’s income statement to Excel — free account

Revolution Medicines, Inc.

Revolution Medicines, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $11.6 million, down 67.3% from fiscal 2022.

Revenue: +1,188.7%
EPS: −18.0%
Free cash flow: −99.1%
Total debt: +322.7%

Quarter to September 2026, against a year earlier

192.98 15.33 +8.63%

Follow RVMD

Alert me

Market cap: $38.1B
P/E: 0.0×
Fwd P/E: −11.9×
Dividend yield: —
F-score: 4/9
Altman Z: 7.73
Beneish M: −4.29
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Revolution Medicines, Inc. (RVMD) revenue by segment, product and region

Revenue by product or service $m

Line	FY2022	FY2021	FY2020	FY2019	FY2018
Collaboration Revenue Member	35 100.00%	29 100.00%	43 100.00%	50 100.00%	—
Collaboration Revenue Related Party	—	—	—	—	19 96.31%
Collaboration Revenues Other	—	—	—	—	1 3.69%
Revenue	35	29	43	50	20

As each company reports them in its 10-K and 10-Q filings, in US dollars. Where a later filing recast a year's segments, the year is shown as recast; a period whose breakdown does not add up to the company's revenue is left out.

Revolution Medicines, Inc. (RVMD) revenue by segment, product and region

Revenue by product or service $m

Stockrow Weekly